InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,830.37
(
-0.50%
)
US TECH 100
19,656.40
(
-1.22%
)
Dow Jones
42,894.39
(
-0.40%
)
Brent Oil
73.99
(
-1.23%
)
Bitcoin
66,738.52
(
1.03%
)
Post# of 661149
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Lady-baron

Send PM Follow Ignore
Followers 15
Posts 1594
Boards Moderated 0
Alias Born 07/22/2005

Lady-baron

Re: AugustaFriends post# 307343

Tuesday, 04/01/2014 9:09:06 AM

Tuesday, April 01, 2014 9:09:06 AM

Post# of 661149
CBLI CBL0137 Combination Studies to Be Presented at 2014 AACR Annual Meeting 5 - 6 April

Intravenous administration of CBL0137 is being evaluated in a Phase 1 trial with patients with metastatic or unresectable advanced solid cancers and lymphomas. Oral administration of CBL0137 is being assessed in a Phase 1 study of patients with advanced solid tumors that are resistant or refractory to current standard treatment. To date, no drug-related serious adverse events have been reported in either trial.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up